In the phase 3 BALATON and COMINO studies, Vabysmo demonstrated vision maintenance and anatomic improvements up to week 72 in macular edema secondary to retinal vein occlusion, or RVO, according to a Genentech press release.
In both studies, Vabysmo (faricimab-svoa) was administered from week 24 to week 72 using a treat-and-extend dosing regimen, allowing patients to extend their treatment interval up to every 4 months while maintaining the vision gains achieved at week 24. Consistent reduction in central subfield thickness indicated rapid, robust and sustained drying of retinal fluid from